PL3053916T3 - Związek mający aktywność agonistyczną wobec receptora somatostatyny i jego farmaceutyczne zastosowanie - Google Patents
Związek mający aktywność agonistyczną wobec receptora somatostatyny i jego farmaceutyczne zastosowanieInfo
- Publication number
- PL3053916T3 PL3053916T3 PL14847684T PL14847684T PL3053916T3 PL 3053916 T3 PL3053916 T3 PL 3053916T3 PL 14847684 T PL14847684 T PL 14847684T PL 14847684 T PL14847684 T PL 14847684T PL 3053916 T3 PL3053916 T3 PL 3053916T3
- Authority
- PL
- Poland
- Prior art keywords
- compound
- pharmaceutical use
- somatostatin receptor
- agonistic activity
- receptor agonistic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2013205027 | 2013-09-30 | ||
| JP2013268902 | 2013-12-26 | ||
| PCT/JP2014/075794 WO2015046482A1 (ja) | 2013-09-30 | 2014-09-29 | ソマトスタチン受容体作動活性を有する化合物およびその医薬用途 |
| EP14847684.9A EP3053916B1 (en) | 2013-09-30 | 2014-09-29 | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3053916T3 true PL3053916T3 (pl) | 2019-06-28 |
Family
ID=52743606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL14847684T PL3053916T3 (pl) | 2013-09-30 | 2014-09-29 | Związek mający aktywność agonistyczną wobec receptora somatostatyny i jego farmaceutyczne zastosowanie |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9643951B2 (pl) |
| EP (1) | EP3053916B1 (pl) |
| JP (1) | JP6380402B2 (pl) |
| KR (1) | KR20160062023A (pl) |
| CN (1) | CN105593221B (pl) |
| AU (1) | AU2014325078B2 (pl) |
| BR (1) | BR112016007078A2 (pl) |
| CA (1) | CA2925651A1 (pl) |
| DK (1) | DK3053916T3 (pl) |
| ES (1) | ES2716151T3 (pl) |
| HK (1) | HK1223356A1 (pl) |
| HU (1) | HUE043374T2 (pl) |
| IL (1) | IL244813A0 (pl) |
| MX (1) | MX2016004088A (pl) |
| PH (1) | PH12016500573B1 (pl) |
| PL (1) | PL3053916T3 (pl) |
| PT (1) | PT3053916T (pl) |
| RU (1) | RU2666352C2 (pl) |
| SG (1) | SG11201602477YA (pl) |
| TW (1) | TWI628175B (pl) |
| WO (1) | WO2015046482A1 (pl) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210134838A (ko) | 2016-07-14 | 2021-11-10 | 크리네틱스 파마슈티칼스, 인크. | 소마토스타틴 조절제 및 그의 용도 |
| EP3581569A4 (en) | 2017-02-08 | 2020-02-19 | ONO Pharmaceutical Co., Ltd. | CONNECTION WITH AGONISTIC SOMATOSTATIN RECEPTOR ACTIVITY AND PHARMACEUTICAL USE THEREOF |
| KR20190121404A (ko) * | 2017-03-16 | 2019-10-25 | 크리네틱스 파마슈티칼스, 인크. | 소마토스타틴 조절제 및 이의 용도 |
| US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| AU2019209469B2 (en) * | 2018-01-17 | 2022-09-08 | Crinetics Pharmaceuticals, Inc. | Process of making somatostatin modulators |
| US11608335B2 (en) | 2018-02-12 | 2023-03-21 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| WO2019240246A1 (ja) * | 2018-06-15 | 2019-12-19 | 小野薬品工業株式会社 | ピペリジノール誘導体の新規な塩および新規結晶形 |
| EP3853218A4 (en) | 2018-09-18 | 2022-02-16 | Crinetics Pharmaceuticals, Inc. | SOMATOSTATIN MODULATORS AND USES THEREOF |
| TW202115008A (zh) * | 2019-08-14 | 2021-04-16 | 美商克林提克斯醫藥股份有限公司 | 非肽生長抑制素(somatostatin)5型受體激動劑及其用途 |
| AU2021341936A1 (en) | 2020-09-09 | 2023-05-25 | Crinetics Pharmaceuticals, Inc. | Formulations of a somatostatin modulator |
| US11773076B2 (en) | 2021-02-17 | 2023-10-03 | Crinetics Pharmaceuticals, Inc. | Crystalline forms of a somatostatin modulator |
| CN116789674A (zh) * | 2022-08-24 | 2023-09-22 | 杭州高光制药有限公司 | Nlrp3炎性小体抑制剂 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0862562B1 (en) | 1995-09-13 | 2001-07-04 | Takeda Chemical Industries, Ltd. | Benzoxazepine compounds, their production and use as lipid lowering agents |
| US6025372A (en) | 1997-04-04 | 2000-02-15 | Merck & Co., Inc. | Somatostatin agonists |
| US6057338A (en) * | 1997-04-04 | 2000-05-02 | Merck & Co., Inc. | Somatostatin agonists |
| AU1285499A (en) * | 1997-10-30 | 1999-05-24 | Merck & Co., Inc. | Somatostatin agonists |
| EP1428531A1 (en) | 1998-05-11 | 2004-06-16 | Takeda Chemical Industries, Ltd. | Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| AU7556800A (en) | 1999-10-07 | 2001-05-10 | Tadeka Chemical Industries, Ltd. | Amine derivatives |
| DE60012213T2 (de) | 1999-11-10 | 2005-07-21 | Takeda Chemical Industries, Ltd. | Fünfgliedrige n-heterocyclen mit hypoglykämischer und hypolipidemischer wirkung |
| FR2802206B1 (fr) | 1999-12-14 | 2005-04-22 | Sod Conseils Rech Applic | Derives de 4-aminopiperidine et leur utilisation en tant que medicament |
| DE60142961D1 (de) | 2000-04-28 | 2010-10-14 | Takeda Pharmaceutical | Antagonisten des melanin-konzentrierenden hormons |
| AU2001256733A1 (en) | 2000-05-16 | 2001-11-26 | Takeda Chemical Industries Ltd. | Melanin-concentrating hormone antagonist |
| EP1437351A4 (en) | 2001-10-19 | 2005-06-01 | Takeda Pharmaceutical | AMINE DERIVATIVE |
| PE20050285A1 (es) * | 2003-06-24 | 2005-06-09 | Novartis Ag | Composicion farmaceutica que comprende analogos ciclicos de somatostatina |
| US20090196912A1 (en) | 2004-07-30 | 2009-08-06 | Gpc Botech Ag | Pyridinylamines |
| TW200726767A (en) | 2005-07-04 | 2007-07-16 | Astrazeneca Ab | Chemical compounds 2 |
| CN101258152A (zh) * | 2005-07-04 | 2008-09-03 | 阿斯利康(瑞典)有限公司 | 作为pde4抑制剂用于治疗炎症和免疫疾病的吡啶并嘧啶衍生物 |
| CA2644929A1 (en) | 2006-03-13 | 2008-05-02 | Merck & Co., Inc. | Somatostatin agonists |
| KR101117931B1 (ko) * | 2006-08-15 | 2012-04-12 | 에프. 호프만-라 로슈 아게 | 페닐, 피리딘 및 퀴놀린 유도체 |
| GB0818241D0 (en) * | 2008-10-06 | 2008-11-12 | Cancer Res Technology | Compounds and their use |
| US9630976B2 (en) | 2012-07-03 | 2017-04-25 | Ono Pharmaceutical Co., Ltd. | Compound having agonistic activity on somatostatin receptor, and use thereof for medical purposes |
-
2014
- 2014-09-29 SG SG11201602477YA patent/SG11201602477YA/en unknown
- 2014-09-29 ES ES14847684T patent/ES2716151T3/es active Active
- 2014-09-29 KR KR1020167008316A patent/KR20160062023A/ko not_active Application Discontinuation
- 2014-09-29 WO PCT/JP2014/075794 patent/WO2015046482A1/ja active Application Filing
- 2014-09-29 TW TW103133704A patent/TWI628175B/zh not_active IP Right Cessation
- 2014-09-29 BR BR112016007078A patent/BR112016007078A2/pt not_active IP Right Cessation
- 2014-09-29 EP EP14847684.9A patent/EP3053916B1/en active Active
- 2014-09-29 RU RU2016111659A patent/RU2666352C2/ru not_active IP Right Cessation
- 2014-09-29 AU AU2014325078A patent/AU2014325078B2/en not_active Ceased
- 2014-09-29 MX MX2016004088A patent/MX2016004088A/es unknown
- 2014-09-29 CA CA2925651A patent/CA2925651A1/en not_active Abandoned
- 2014-09-29 CN CN201480053967.4A patent/CN105593221B/zh not_active Expired - Fee Related
- 2014-09-29 US US15/025,739 patent/US9643951B2/en active Active
- 2014-09-29 HU HUE14847684A patent/HUE043374T2/hu unknown
- 2014-09-29 PT PT14847684T patent/PT3053916T/pt unknown
- 2014-09-29 DK DK14847684.9T patent/DK3053916T3/en active
- 2014-09-29 JP JP2015539407A patent/JP6380402B2/ja not_active Expired - Fee Related
- 2014-09-29 PL PL14847684T patent/PL3053916T3/pl unknown
-
2016
- 2016-03-29 IL IL244813A patent/IL244813A0/en unknown
- 2016-03-29 PH PH12016500573A patent/PH12016500573B1/en unknown
- 2016-10-04 HK HK16111532.4A patent/HK1223356A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105593221B (zh) | 2017-09-22 |
| JP6380402B2 (ja) | 2018-08-29 |
| AU2014325078B2 (en) | 2018-10-25 |
| AU2014325078A1 (en) | 2016-04-21 |
| TWI628175B (zh) | 2018-07-01 |
| SG11201602477YA (en) | 2016-05-30 |
| PH12016500573A1 (en) | 2016-07-04 |
| CN105593221A (zh) | 2016-05-18 |
| RU2016111659A3 (pl) | 2018-03-20 |
| EP3053916A4 (en) | 2017-03-08 |
| DK3053916T3 (en) | 2019-04-15 |
| BR112016007078A2 (pt) | 2017-12-12 |
| TW201602092A (zh) | 2016-01-16 |
| HUE043374T2 (hu) | 2019-08-28 |
| US20160311794A1 (en) | 2016-10-27 |
| EP3053916B1 (en) | 2019-01-30 |
| US9643951B2 (en) | 2017-05-09 |
| PH12016500573B1 (en) | 2016-07-04 |
| WO2015046482A1 (ja) | 2015-04-02 |
| RU2666352C2 (ru) | 2018-09-07 |
| IL244813A0 (en) | 2016-05-31 |
| CA2925651A1 (en) | 2015-04-02 |
| KR20160062023A (ko) | 2016-06-01 |
| MX2016004088A (es) | 2016-06-06 |
| EP3053916A1 (en) | 2016-08-10 |
| HK1223356A1 (zh) | 2017-07-28 |
| PT3053916T (pt) | 2019-03-26 |
| RU2016111659A (ru) | 2017-11-13 |
| ES2716151T3 (es) | 2019-06-10 |
| JPWO2015046482A1 (ja) | 2017-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL244813A0 (en) | A compound with agonistic activity for the somatostatin receptor and its medicinal use | |
| EP2871179A4 (en) | CONNECTION WITH AGONISTIC EFFECT ON THE SOMATOSTATIN RECEPTOR AND ITS USE FOR MEDICAL PURPOSES | |
| ZA201503146B (en) | Il-6 antagonists and uses thereof | |
| HK1254296A1 (zh) | 治療性化合物和其用途 | |
| GB201320729D0 (en) | Therapeutic compounds and their use | |
| IL268444A (en) | Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof | |
| IL245471B (en) | Fluorinated compounds as alpha v integrin receptor antagonists | |
| HK1217092A1 (zh) | 治療性化合物及其用途 | |
| HRP20181536T1 (hr) | Supstituirani piperidinil-tetrahidrokinolini i njihova uporaba kao antagonisti alfa-2c adrenoreceptora | |
| EP3006431A4 (en) | TIZOXANID CARBAMATE AND PHARMACEUTICAL USE THEREOF | |
| HK1219691A1 (zh) | 醫藥組成物及其用途 | |
| GB201311361D0 (en) | Compounds and their therapeutic use | |
| GB201308736D0 (en) | Compounds and their therapeutic use | |
| EP3065736A4 (en) | Glucagon receptor antagonist compounds, compositions thereof, and methods of use | |
| HK1216101A1 (zh) | 用作促性腺激素釋放激素受體拮抗劑的螺二氫吲哚衍生物 | |
| EP2986627A4 (en) | EPH-A RECEPTOR INHIBITORS AND USES THEREOF | |
| EP2832732A4 (en) | DRUG ENHANCING THE ACTIVITY OF PPAR AGONISTS | |
| GB201317804D0 (en) | Therapeutic compounds and their use | |
| GB201316173D0 (en) | Compounds and their therapeutic use | |
| GB201304625D0 (en) | New pharmaceutical composition | |
| GB201307677D0 (en) | Compounds and their therapeutic use |